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Abstract The insulin-like growth factor binding proteins
(IGFBPs) are responsible for regulation of the effects and the
bioavailability of the insulin-like growth factors (IGFs). We
screened for circulating fragments of human IGFBP-5 in human
hemofiltrate. Identification of IGFBP-5 peptides in the fractions
of our peptide bank generated from hemofiltrate was performed
by their immunoreactivity and their capacity to bind IGF-I.
Different fragments of IGFBP-5 with molecular sizes from 12 to
25 kDa were identified. C-terminal peptides of IGFBP-5 with
molecular masses of 13.3 and 13.5 kDa were purified by
consecutive chromatographic steps and sequenced. Sequence
analysis of the peptides revealed the (double) sequences
(K)FVGGAENXAHPRII and MVPRAVYLPNXDRKG. In
addition, a smaller fragment with Mr 2722 of the central
IGFBP-5 region was purified and showed the sequence
HTRISELKAEAVKKDRRKKLTQS (residues 121^143) indi-
cating plasma proteolysis of IGFBP-5 C-terminal to amino acids
Lys-120, Ser-143, Lys-144, and Arg-188. According to mass
spectrometric and sequence analysis, Thr-152 was shown to be
O-glycosylated. Fractions containing C-terminal IGFBP-5 frag-
ments revealed significant IGF-I binding properties. Our results
indicate that plasma proteolysis of IGFBP-5 preferentially
occurs C-terminally to basic residues and generates different
C-terminal fragments, possibly acting in an IGF-dependent
manner and bearing intrinsic biological functions.
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1. Introduction
The insulin-like growth factor-binding proteins (IGFBPs)
are a family of at least six related proteins involved in regu-
lating the e¡ects and the bioavailability of the insulin-like
growth factors, IGF-I and IGF-II, which are responsible for
growth and di¡erentiation of cells and tissues [1,2].
IGFBPs are capable of either potentiating or inhibiting the
e¡ects of the IGFs, although they have also been shown to
exhibit intrinsic activities independent of their binding to
IGFs that modulate cell proliferation [3,4].
IGFBP-5 in particular was found to act via an IGF-inde-
pendent mechanism on osteoblast proliferation [5]. In this
context, the C-terminal amino acid residues of IGFBP-5 are
supposed to be responsible for its biological action by inter-
action with a putative IGFBP-5 receptor [6] or by intracellular
translocation and nuclear interaction [7].
The structure of the IGFBPs can be described as consisting
of two cysteine-rich, structure-stable domains, the N- and C-
terminal domains, and a non-conserved central region con-
necting these domains. Limited proteolysis of the IGFBPs
into these two main fragments was demonstrated in vitro
[3,8] and in vivo [9].
Proteolysis of IGFBPs is caused by a variety of extracellu-
lar proteases, a mechanism that is recognized as essential in
the regulation of IGF bioavailability [10^12].
Since all six IGFBPs were detectable in human plasma,
mostly occurring as high molecular weight complexes of 40^
50 or 150 kDa, little is known about exact in vivo degradation
and presence of low molecular weight IGFBP fragments [1].
Therefore, the aim of this study was to isolate circulating
fragments of IGFBP-5 from human hemo¢ltrate (HF) [13]
to determine cleavage sites and characterize the structural
and functional properties of the fragments themselves.
Human HF is generated during blood ¢ltration of patients
with chronic renal failure and was shown to be an excellent
source for the isolation of regulatory peptides with
Mr6 20 000 [14,15].
For the isolation of novel IGFBP-5 fragments, we started
screening in the fractions of the HF peptide bank generated
according to our standard procedure [13]. The screening in-
cluded Western immunoblot, IGF-I ligand-blot analysis, and
determination of the molecular size of the detected peptides
by matrix assisted laser desorption ionization-mass spectrom-
etry (MALDI-MS). We identi¢ed several di¡erent IGFBP-5
fragments in the peptide bank and puri¢ed novel C-terminal
fragments of IGFBP-5 retaining IGF binding capacity. The
peptides reveal O-glycosylation and indicate that plasma pro-
teolysis of IGFBP-5 occurs preferentially C-terminally to ba-
sic amino acid residues.
2. Materials and methods
2.1. Preparation of peptide extracts from human hemo¢ltrate
Peptides of human blood ultra¢ltrate are prepared according to our
concept and IPF laboratory standards [13,14]. In brief, the crude
peptide extract is obtained from 10 000 l hemo¢ltrate (HF). Immedi-
ately after blood ¢ltration, the ¢ltrate is cooled to 4‡C and condi-
tioned to a pH of 2.7. After binding the peptides to an ion-exchange
column, a batch elution follows. For the ¢rst separation step, stepwise
batch elution is performed using a 10-l cation-exchange column and
seven di¡erent bu¡ers increasing the pH from 3.6 to 9.0. The resulting
pools (15^25 l) are immediately fractionated by reverse-phase chro-
matography. Each pool is applied to a Source RP-C column (15 Wm,
10U12.5 cm; Pharmacia, Freiburg, Germany) and separation is per-
formed at a £ow rate of 200 ml/min by an 8-l gradient from 100% A
to 60% B (A: water, 10 mM HCl; B: 80% acetonitrile, 10 mM HCl).
Fractions of 200 ml are collected, monitoring the absorbance at 280
nm. Aliquots of these peptide bank fractions corresponding to a 2-l
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equivalent of hemo¢ltrate are lyophilized and used for the experi-
ments as indicated below.
2.2. Further liquid chromatography
Aliquots of the peptide bank fractions corresponding to 100 ml
equivalent of HF were analyzed by Western immunoblot and Western
ligand-blot as described below.
The fractions showing both immunoreactivity and IGF-binding ca-
pacity were selected for further puri¢cation and analyzed by MALDI-
MS.
To achieve further puri¢cation the selected fractions were applied to
a preparative C18-column (15^20 Wm, 30 nm, 4.7U30 cm; Vydac,
Hesperia, USA). 0.1% tri£uoroacetic acid and 80% acetonitrile in
water and 0.1% tri£uoroacetic acid were the solvents in gradient elu-
tion. Selected single fractions were loaded onto a cation exchange
column (5 Wm, 300 Aî , 10U50 mm Pepkat; Biotek, Oº stringen, Ger-
many) and separated by a gradient elution using 20 mM sodium-
phosphate bu¡er, pH 3.0, or 20 mM sodium phosphate bu¡er, pH
3.0, containing 1 M NaCl. Further puri¢cation of selected fractions
was performed using an analytical C18-column (5 Wm, 30 nm, 1U25
cm; Vydac) with the mentioned RP-solvents in gradient elution.
2.3. Peptide analysis
Mass determination of the puri¢ed peptides was carried out on a
Sciex API III quadrupole mass spectrometer (Sciex; Perkin-Elmer,
Langen, Germany) with an electrospray interface (ESI-MS), mass
determination in the fractions on a LaserTec RBT II MALDI-MS
(PerSeptive Biosystems, Freiburg, Germany) as described previously
[16]. Peptide sequencing was performed on a 473 A gas-phase se-
quencer (Applied Biosystems, Weiterstadt, Germany) by Edman deg-
radation with on-line detection of phenylthiohydantoin-amino acids
using the standard protocol recommended by the manufacturer. To
separate the disul¢de-bridged 13-kDa IGFBP-5 isoforms, the native
peptides were reduced with 2-mercaptoethanol and alkylated at cys-
teine residues with iodoacetamide using standard conditions. The car-
boxyamidomethyl-alkylated peptides were puri¢ed by RP-HPLC, an-
alyzed by mass spectrometry, and sequenced.
2.4. SDS-PAGE and electrotransfer
Aliquots of the HPLC fractions were lyophilized, reconstituted in
sample bu¡er and subjected to an SDS-PAGE according to Schaºgger
and Jagow [17] in Mini-Protean systems (Bio-Rad, Munich, Germany)
at 150 V for 2 h. Molecular mass standards of 4^210 kDa (SeeBlue;
NOVEX, O¡enbach/Main, Germany) were used. The separated pep-
tides were transferred to a hydrophilic polyvinylidene di£uoride
(PVDF) membrane at 7 V for 2 h using a semi-dry electrophoretic
transfer unit (Bio-Rad). The membrane was blocked with 5% pow-
dered skimmed milk in Tris-bu¡ered saline (TBS; 10 mM Tris, 150
mM NaCl, pH 8.0) containing 0.05% Triton X-100 at 4‡C overnight
or for 1 h at room temperature.
2.5. IGFBP-5 immunoblotting
Electroblotted and blocked PVDF membrane was incubated with
rabbit rhIGFBP-5 antiserum (Upstate Biotechnology, Lake Placid,
NY, USA) diluted to 1:1000 in TBS containing 0.05% Triton X-100
at 4‡C overnight (or for 2 h at room temperature). The membrane was
washed in TBS containing 0.05% Triton X-100 and then incubated
with anti-rabbit IgG coupled to alkaline phosphatase (Sigma, Deisen-
hofen, Germany) in the same bu¡er. Afterwards, the nitrocellulose
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Fig. 1. IGFBP-5 immunoblotting. Fractions of the hemo¢ltrate pep-
tide bank were separated by PAGE, electroblotted to a PVDF
membrane, and incubated with rhIGFBP-5 antiserum. After devel-
opment of the blot, IGFBP-5 immunoreactivity was detected in
fractions of pH pool 3, pH pool 5, pH pool 6, and pH pool 7. The
puri¢ed C-terminal IGFBP-5 fragments originated from fractions of
pH pool 6 (lane 8) containing a strong immunoreactivity in the
range of 16 kDa.
C
Fig. 2. Puri¢cation of the 16-kDa IGFBP-5 immunoreactivity from
pH pool 6 chromatograms and pertinent Western immunoblot anal-
ysis. A: Preparative cation exchange chromatography and pH pool
fractionation of 10 000 l human hemo¢ltrate. In this ¢rst separation
step, peptides were eluted batchwise by means of a pH gradient. B:
RP-HPLC fractionation of the peptides derived from pH pool 6
(marked in A). Aliquots of this chromatography were analyzed by
immunoblot and ligand-blot as described in Section 2. C: Semi-
preparative RP-HPLC of the active fraction from B. D: Analytical
cation exchange chromatography of the marked fraction from C. E:
Analytical RP-HPLC of the marked fraction from D. The immu-
noreactive fractions shown in E were analyzed by MALDI- and
ESI-MS, and sequenced.
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was washed ¢rst in TBS containing 0.05% Triton X-100, then in TBS,
and ¢nally with 10 mM Tris, 10 mM NaCl, and 10 mM MgCl2, pH
9.5.
Bands were developed using a bromochloroindolyl phosphate/nitro-
blue tetrazolium substrate system as recommended by the manufac-
turer (Sigma).
2.6. Ligand blotting
Ligand blots were performed according to Hossenlopp et al. [18]
using recombinant human IGFBP-5 (Boehringer Mannheim, Penz-
berg, Germany) as a control. IGFs (PeproTech, London, UK) were
iodinated by the chloramine T method using standard conditions.
Brie£y, aliquots of the HPLC fractions and di¡erent amounts of the
puri¢ed fragments and complete rh IGFBP-5 were placed directly
onto nitrocellulose sheets (5U5 mm). The membrane sheets were
dried for 10 min at room temperature, and then incubated in blot
bu¡er (50 mM Tris, 0.9% NaCl and 0.5% gelatine, pH 7.4) at 4‡C
overnight, followed by incubation in blot bu¡er containing 0.05%
Triton X-100 and 125I-IGFs in a ¢nal concentration of 300 000 cpm/
ml at 4‡C overnight. Afterwards, the nitrocellulose was washed three
times in blot bu¡er containing 0.05% Triton X-100, dried at room
temperature, and the amount of bound radioactivity was determined
using a Q counter (1470 Wallac Wizard; Pharmacia, Turku, Finland).
3. Results and discussion
3.1. Screening for fragments of IGFBP-5
Isolation of bioactive peptides from crude biological sour-
ces depends preliminarily on the structural and biological fea-
tures of the selected peptide and therefore has to be optimized
in each particular case. We attempted isolation of circulating
fragments of the insulin-like growth factor-binding proteins
(IGFBPs) and developed a strategy by characterizing di¡erent
biochemical and immunochemical parameters before starting
the puri¢cation. Screening for IGFBP-5 fragments was started
in the 400 fractions of the peptide bank prepared from human
hemo¢ltrate (HF) [13]. These fractions were generated by
stepwise batch elution of 10 000 l hemo¢ltrate with seven bu¡-
ers with each increasing pH (pH pools; Fig. 2A) and subse-
quent RP-HPLC fractionation of each pH pool (Fig. 2B).
First, Western immunoblot analysis was carried out and
gave a general overview of the IGFBP-5 immunoreactive sub-
stances in our peptide bank. Several immunoreactive fractions
were detectable (Fig. 1). For example, signi¢cant IGFBP-5
immunoreactivity in the range of 25 kDa was detected in
fractions of pH pool 3, and a prominent 16-kDa band was
visualized in pH pool 6. Furthermore, strong IGFBP-5 immu-
noreactivity in the range of 16 kDa was monitored in pH pool
7 where minor bands with molecular sizes of 20^25 kDa also
occurred. In addition, weak IGFBP-5 immunoreactivity in the
range of 30 kDa was detected in pH pool 5. The mature
IGFBPs strongly bind both IGF-I and IGF-II with dissocia-
tion constants (Kd) of 1039 to 10310 M. The mechanism of
IGF binding is proposed to depend on two binding sites with-
in the IGFBPs. Both the N-terminal and the C-terminal
IGFBP regions participate in IGF binding and corresponding
IGFBP fragments have been shown to bind the IGFs with
reduced a⁄nity [9,19,20]. To prevent the puri¢cation of
non-IGFBP peptides, which have shown cross-reactivity to
the IGFBP antisera used, we examined the IGF-I binding
capacity of selected immunoreactive fractions. Using ligand-
blot analysis with radiolabeled IGF-I, some immunoreactive
fractions showed signi¢cant IGF binding capacity (Fig. 3A).
On the other hand, other immunoreactive fractions did not
possess any signi¢cant a⁄nity for IGF-I. The results of the
initial immunoscreening and ligand-blot analysis in the blood
¢ltrate are summarized in Table 1.
3.2. Isolation of C-terminal IGFBP-5 immunoreactive peptides
For further biochemical characterization, we performed
mass spectrometrical analysis of selected fractions which
showed both IGF binding and IGFBP-5 immunoreactivity.
Therefore we used MALDI-MS, which was recently shown
to be a valuable method of guiding the puri¢cation of bioac-
tive peptides from complex biological mixtures [16].
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Fig. 3. A: Ligand-blot analysis of the immunoreactive fractions
(Fig. 2B) from pH pool 6 using radiolabeled IGF-I. IGF-I binding
to fractions 25^27 from pH pool 6 each containing 100 ml equiva-
lent of hemo¢ltrate was comparable to IGF-I binding to 50 ng com-
plete rhIGFBP-5 (BP-5). B: MALDI-MS spectra of the fraction
(marked in Fig. 2E) containing C-terminal IGFBP-5 peptides and
corresponding molecular masses of the IGFBP-5 peptides deter-
mined by ESI-MS. Note contaminant peptide with Mr 14.5 kDa
(human pancreatic ribonuclease).
Table 1
IGFBP-5 immunoreactive fractions and pertinent ligand-blot analy-
sis in the hemo¢ltrate peptide bank
pH pool Lane IGFBP-5 kDa LB
3 6 ++ 23 3
3 7 + 23 n.d.
3 8 + 23 n.d.
5 7 + 30 +
5 8 + 30 3
5 9 + 30 n.d.
5 10 + 30, 23 n.d.
5 11 + 30, 23 3
6 8 +++ 16 +
6 9 + 16 +
7 2 + 20 3
7 3 + 23, 20 3
7 4 + 20 n.d.
7 8 ++ 16 +
LB, ligand-blot analysis; n.d., not determined.
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For initial puri¢cation, we selected fraction 25 of pH pool 6
(corresponding to lane 8 in Fig. 1) which contained an immu-
noreactive IGFBP-5 peptide in the range of 16 kDa and addi-
tionally showed a signi¢cant binding a⁄nity for IGF-I (Table
1; Fig. 3A).
For isolation, the selected fraction (marked in Fig. 2B) was
loaded onto a preparative RP-C18 column. The run was per-
formed using a linear acetonitrile gradient and the generated
fractions were analyzed for immunoreactivity and IGF-I bind-
ing (Fig. 2C). Those fractions showing both immunoreactivity
and IGF-binding capacity were applied to a cation exchange
column and separated by a linear sodium chloride gradient in
phosphate bu¡er (Fig. 2D).
The generated fractions were analyzed as mentioned above.
To achieve further puri¢cation the selected fractions (marked
in Fig. 2D) were chromatographed using an analytical RP-C4
column (Fig. 2E). The strong immunoreactive fractions shown
in Fig. 2E were sequenced using conventionel Edman chem-
istry. The N-terminal (double) sequences were (K)FVGGA-
ENXAHPRII and MVPRAVYLPNXDRKG which corre-
spond exactly to the sequence of human IGFBP-5, amino
acid residues 144^159, 145^159, and 189^204, indicating
plasma proteolysis of IGFBP-5 C-terminal to amino acids
Gln-143, Lys-144, and Arg-188 (Fig. 4). MALDI and ESI
mass spectra of the fraction marked in Fig. 2E revealed
the existence of three di¡erent IGFBP-5 peptides (Fig. 3B).
The ESI masses of the IGFBP-5 peptides were determined
to be 13 542 þ 2.8 Da, 13 462 þ 2.1 Da, and 13 253 þ 2.1 Da
(Fig. 3B). Sequencing of N-terminal Met-189 revealed that
one peptide contains an intramolecular cleavage. Since
only molecular masses higher than 13 kDa were determined,
the generated fragments must be connected by a disul¢de
bond.
3.3. Biochemical characterization of the peptides
Since the three puri¢ed peptides were very similar in se-
quence (Fig. 4), mass (Fig. 3B), and structure we were not
able to separate the single, native substances from each other
by chromatography. Therefore, we reduced and alkylated the
peptides at cysteine residues. After separation of the amidoal-
kylated peptides by RP-HPLC, mass spectrometric and se-
quence analysis revealed the occurrence of IGFBP-5144ÿ187
(Mr 6036) and IGFBP-5188ÿ252 (Mr 7780) (Fig. 4). The peptide
IGFBP-5144ÿ187 has a calculated mass of 5091 Da, including
one carboxyamidoalkylated cysteine, and therefore showed a
mass increase of 947 Da caused by glycosylation.
The theoretical mass of the C-terminal IGFBP-5 domain
(from Lys-144 to Glu-252), calculated from the cDNA of
IGFBP-5 [21], amounts to 12 503 Da and is lower than all
three masses of the native fragments determined by ESI-MS.
Therefore, glycosylation of the three peptides seems to be
probable. Although N-linked glycosylation is described for
IGFBP-3 [22] and -4 [23] and extensive O-linked glycosylation
is described for IGFBP-6 [24,25], little is known about O-
glycosylation of IGFBP-5 [26]. When sequencing the native
and the alkylated peptides, no amino acid was detectable at
position 152 (Thr). This indicates a blocked Thr-152 by an O-
glycosylation. The molecular mass di¡erence between the cal-
culated and the electrospray masses amounts to 947 Da (Fig.
4) which might be caused by a glycosylation containing one
hexose, one N-acetylhexosamine and two N-acetylneuraminic
acids. A corresponding O-glycosylation was described for
IGFBP-6 [25].
3.4. Plasma proteolysis of IGFBP-5
The isolation of a circulating C-terminal IGFBP-5 domain
is in agreement with earlier observations of IGFBP proteolysis
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Fig. 4. Sequence and mass spectrometric analysis of the IGFBP-5 peptides from hemo¢ltrate ^ plasma proteolysis of IGFBP-5. The cysteine-
rich conserved regions of IGFBP-5 are indicated as shaded boxes. Sequenced amino acids are in bold letters. Plasma proteolysis of IGFBP-5
was detected in the central non-conserved region and between cysteine 1 and cysteine 2 generating three di¡erent (glycosylated) peptides com-
prising the C-terminal domain with molecular masses of 13.2^13.5 kDa. In addition, one smaller 3-kDa peptide of the central region was
found. Note the intramolecular cleavage site between Arg-188 and Met-189 and O-glycosylation of Thr-152. The analysis of the reduced and
amidoalkylated C-terminal IGFBP-5 peptides was in accordance with the data obtained from the native peptides.
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in vitro, where the generation of two main proteolytic prod-
ucts of IGFBPs was observed ^ one representing the N-termi-
nal domain, the other representing the C-terminal domain
[27,28]. The C-terminal IGFBP-5 fragments obviously re-
tained a signi¢cant IGF-I binding a⁄nity (Fig. 3A), which
might be lower compared to the mature IGFBP-5. In general,
proteolysis of the IGFBPs generates fragments with lower or
no IGF a⁄nity and therefore enhances the IGF availability
for the IGF-I receptor [1].
In addition, we puri¢ed a fragment with Mr 2722 of the
central IGFBP-5 region from pH pool 6 of our hemo¢ltrate
peptide bank by routinely performed sequence analysis of
circulating human peptides. The fragment showed the se-
quence HTRISELKAEAVKKDRRKKLTQS, therefore
spanning from Thr-121 to Ser-143 of IGFBP-5 (Fig. 4). In
conclusion, our data indicate that plasma proteolysis of hu-
man IGFBP-5 occurs C-terminally to amino acids Lys-120,
Ser-143, Lys-144, and Arg-188. Although the proteases re-
sponsible for its degradation remain as yet unde¢ned, enzymes
with speci¢city such as trypsin might be responsible for plas-
ma proteolysis of IGFBP-5, since basic amino acids seem to
be favored cleavage sites. In addition, we were able to detect
further IGFBP-5 immunoreactive peptides in the hemo¢ltrate
peptide bank ranging from 12 to 25 kDa. Based on the knowl-
edge of the circulating IGFBP-5121ÿ143, the existence of an N-
terminal IGFBP-5 fragment spanning residues 1^120 would
be expected.
3.5. Conclusions
Human hemo¢ltrate was recently described to be a valuable
source for the isolation of regulatory peptides with
Mr6 20 000 [14,15]. Our approach to isolate a binding protein
by its immunoreactivity, the IGF-I binding capacity, and
MALDI-MS analysis of selected fractions should be of special
advantage for isolation of IGFBP fragments. Nevertheless,
smaller IGFBP fragments with reduced or lost a⁄nity for
the IGFs, or with only weak immunoreactivity could not be
detected by the methods used. MALDI-MS was recently
shown to be a suitable method for the puri¢cation of bioac-
tive peptides from complex biological mixtures if their molec-
ular masses are known [16].
In bone metabolism, IGFBP-5 was found to contribute to
osteoblast proliferation and bone formation in an IGF-inde-
pendent manner [5]. IGFBP-5 and IGFBP-5 fragments are
described to act stimulatively in synergism with the IGFs ^
possibly acting via a membrane receptor of its own [5,6,29].
Interestingly, a C-terminal fragment of IGFBP-5 was shown
to inhibit the interaction of IGFBP-5 to its putative 420-kDa
signaling receptor [6]. C-terminal residues of IGFBP-5 were
also found to be involved in the intracellular translocation
and the putative nuclear interaction of IGFBP-5 [7]. There-
fore, it seems to be probable that the circulating C-terminal
IGFBP-5 fragments may have an intrinsic biological e¡ect on
cell growth and di¡erentiation.
Meanwhile, we are currently in the process of isolating fur-
ther fragments of IGFBPs from human hemo¢ltrate. Further
characterization of the peptides will include structural aspects
and will examine the biological relevance of the peptides with
respect to the important (patho)physiological role of the IGF
system, focusing on intrinsic, IGF-independent e¡ects of
IGFBP fragments.
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